Our research will bring positive benefits to patients

Our proprietary PEPR^® platform features chemical modification, target and gene selection, siRNA sequence design and optimization, and advanced delivery technologies. These features enhance siRNA stability and target engagement for more potent and durable therapeutics. The chemical modifications minimize off-target effects and improve the safety profile, resulting in a potentially wider therapeutic window that is critical for chronic disease treatment. 

In addition, we are advancing extrahepatic deliveries to expand the reach of siRNA beyond liver into tissues such as adipose, skeletal muscle, heart, kidney, and the central nervous system (CNS). We have protected our platform in our growing portfolio of filed and issued patents encompassing our chemistry tool kit, specific gene sequences, and other aspects of our platform.